Study of a new drug for people with lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new medication, SKB518, for people with non-small cell or small cell lung cancer who have at least one measurable tumor and are in fairly good health. It aims to see if the drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell or small cell lung cancer.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your doctor expects you to live at least 12 more weeks.
- You do not have serious heart problems, a history of lung inflammation needing steroids, or an active infection like HIV or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKB571 in people with advanced non-small cell lung cancer. The goal is to see if it can help shrink tumors or slow cancer growth.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new drug combination for people with a type of lung cancer that has spread or cannot be removed by surgery. It compares the new combination to the current standard treatment to see which works better.
This trial tests a new drug called SKB500, given alone or with other treatments, for people with extensive-stage small cell lung cancer that has spread. It may be an option for those who have had little or no prior treatment.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Hear when a new Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.